ICFSR Task Force Perspective on Biomarkers for Sarcopenia and Frailty
Biomarkers of frailty and sarcopenia are essential to advance the understanding of these conditions of aging and develop new diagnostic tools and effective treatments. The International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force - a group of academic and industry scientists fro...
Gespeichert in:
| Veröffentlicht in: | The Journal of Frailty & Aging 2020-01, Vol.9 (1), p.4-8 |
|---|---|
| Hauptverfasser: | , , , , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 8 |
|---|---|
| container_issue | 1 |
| container_start_page | 4 |
| container_title | The Journal of Frailty & Aging |
| container_volume | 9 |
| creator | Rodriguez-Mañas, L. Araujo de Carvalho, I. Bhasin, S. Bischoff-Ferrari, H. A. Cesari, M. Evans, W. Hare, J. M. Pahor, M. Parini, A. Rolland, Y. Fielding, R. A. Walston, J. Vellas, B. |
| description | Biomarkers of frailty and sarcopenia are essential to advance the understanding of these conditions of aging and develop new diagnostic tools and effective treatments. The International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force - a group of academic and industry scientists from around the world — met in February 2019 to discuss the current state of biomarker development for frailty and sarcopenia. The D3Cr dilution method, which assesses creatinine excretion as a biochemical measure of muscle mass, was suggested as a more accurate measure of functional muscle mass than assessment by dual energy x-ray absorptiometry (DXA). Proposed biomarkers of frailty include markers of inflammation, the hypothalamic-pituitary-adrenal (HPA) axis response to stress, altered glucose insulin dynamics, endocrine dysregulation, aging, and others, acknowledging the complex multisystem etiology that contributes to frailty. Lack of clarity regarding a regulatory pathway for biomarker development has hindered progress; however, there are currently several international efforts to develop such biomarkers as tools to improve the treatment of individuals presenting these conditions. |
| doi_str_mv | 10.14283/jfa.2019.32 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_hal_p</sourceid><recordid>TN_cdi_hal_primary_oai_HAL_hal_04538570v1</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2933187445</sourcerecordid><originalsourceid>FETCH-LOGICAL-c429t-fb64454d7e427df9c0870c38140d7f52b90685734029485eb3d5a6578f2304133</originalsourceid><addsrcrecordid>eNptkc1LAzEQxYMoKtqbZwl4UXBrkkk2yVFLq0JB0XoO2d2srm43NWkL_e9NrR8gniZMfrx5Mw-hI0r6lDMFF6-17TNCdR_YFtpnTELGgejt9TsnGQVO91AvxqYgXGuVU6C7aA8YFYQRuY-Gt4PR4wOe2PiGRz6UDt-7EGeunDdLh32Hrxo_teEtNXHtA360ofQz1zUW267Co2Cbdr46RDu1baPrfdUD9DQaTgY32fju-nZwOc5KzvQ8q4ucc8Er6TiTVa1LoiQpQVFOKlkLVmiSKyGBE6a5Eq6ASthcSFUzIJwCHKCzje6Lbc0sNMnZynjbmJvLsVn3CBeQFMiSJvZ0w86Cf1-4ODfTJpaubW3n_CIaBlKkI3DFEnryB331i9ClTQzTAFTJZDtR5xuqDD7G4OofB5SYzzRMSsOs0zCwFj3-El0UU1f9wN-3T0C2AWL66p5d-J36r-AHgxWPBQ</addsrcrecordid><sourcetype>Open Access Repository</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2933187445</pqid></control><display><type>article</type><title>ICFSR Task Force Perspective on Biomarkers for Sarcopenia and Frailty</title><source>MEDLINE</source><source>ProQuest Central (Alumni Edition)</source><source>Applied Social Sciences Index & Abstracts (ASSIA)</source><source>ProQuest Central Korea</source><source>ProQuest Central UK/Ireland</source><source>SpringerLink Journals - AutoHoldings</source><source>ProQuest Central</source><creator>Rodriguez-Mañas, L. ; Araujo de Carvalho, I. ; Bhasin, S. ; Bischoff-Ferrari, H. A. ; Cesari, M. ; Evans, W. ; Hare, J. M. ; Pahor, M. ; Parini, A. ; Rolland, Y. ; Fielding, R. A. ; Walston, J. ; Vellas, B.</creator><creatorcontrib>Rodriguez-Mañas, L. ; Araujo de Carvalho, I. ; Bhasin, S. ; Bischoff-Ferrari, H. A. ; Cesari, M. ; Evans, W. ; Hare, J. M. ; Pahor, M. ; Parini, A. ; Rolland, Y. ; Fielding, R. A. ; Walston, J. ; Vellas, B.</creatorcontrib><description>Biomarkers of frailty and sarcopenia are essential to advance the understanding of these conditions of aging and develop new diagnostic tools and effective treatments. The International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force - a group of academic and industry scientists from around the world — met in February 2019 to discuss the current state of biomarker development for frailty and sarcopenia. The D3Cr dilution method, which assesses creatinine excretion as a biochemical measure of muscle mass, was suggested as a more accurate measure of functional muscle mass than assessment by dual energy x-ray absorptiometry (DXA). Proposed biomarkers of frailty include markers of inflammation, the hypothalamic-pituitary-adrenal (HPA) axis response to stress, altered glucose insulin dynamics, endocrine dysregulation, aging, and others, acknowledging the complex multisystem etiology that contributes to frailty. Lack of clarity regarding a regulatory pathway for biomarker development has hindered progress; however, there are currently several international efforts to develop such biomarkers as tools to improve the treatment of individuals presenting these conditions.</description><identifier>ISSN: 2260-1341</identifier><identifier>EISSN: 2273-4309</identifier><identifier>DOI: 10.14283/jfa.2019.32</identifier><identifier>PMID: 32150207</identifier><language>eng</language><publisher>Cham: Springer International Publishing</publisher><subject>Advisory Committees ; Age ; Aging ; Biological markers ; Biomarkers ; Chronic illnesses ; Clinical trials ; Congresses as Topic ; Creatinine ; Cytokines ; Etiology ; Frailty ; Geriatrics/Gerontology ; Glucose ; Hormones ; Humans ; Hypothalamic-pituitary-adrenal axis ; Inflammation ; Insulin ; Insulin-like growth factors ; Internal Medicine ; Life Sciences ; Magnetic resonance imaging ; Medicine ; Medicine & Public Health ; Musculoskeletal system ; Neutrophils ; Proteins ; Rheumatology ; Santé publique et épidémiologie ; Sarcopenia ; Special Article ; Task forces ; Tumor necrosis factor-TNF ; Urine</subject><ispartof>The Journal of Frailty & Aging, 2020-01, Vol.9 (1), p.4-8</ispartof><rights>The Author(s) 2019</rights><rights>The Author(s) 2019. This work is published under http://creativecommons.org/licenses/by/4.0/ (the “License”). Notwithstanding the ProQuest Terms and Conditions, you may use this content in accordance with the terms of the License.</rights><rights>Attribution</rights><lds50>peer_reviewed</lds50><oa>free_for_read</oa><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c429t-fb64454d7e427df9c0870c38140d7f52b90685734029485eb3d5a6578f2304133</citedby><cites>FETCH-LOGICAL-c429t-fb64454d7e427df9c0870c38140d7f52b90685734029485eb3d5a6578f2304133</cites><orcidid>0000-0002-1157-0215 ; 0009-0003-9486-9144 ; 0000-0002-7678-5065</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.proquest.com/docview/2933187445?pq-origsite=primo$$EHTML$$P50$$Gproquest$$H</linktohtml><link.rule.ids>230,314,777,781,882,12827,21369,21370,21372,27905,27906,30980,33511,33512,33725,33726,33986,33987,43640,43786,43934,64364,64366,64368,72218</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32150207$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink><backlink>$$Uhttps://hal.science/hal-04538570$$DView record in HAL$$Hfree_for_read</backlink></links><search><creatorcontrib>Rodriguez-Mañas, L.</creatorcontrib><creatorcontrib>Araujo de Carvalho, I.</creatorcontrib><creatorcontrib>Bhasin, S.</creatorcontrib><creatorcontrib>Bischoff-Ferrari, H. A.</creatorcontrib><creatorcontrib>Cesari, M.</creatorcontrib><creatorcontrib>Evans, W.</creatorcontrib><creatorcontrib>Hare, J. M.</creatorcontrib><creatorcontrib>Pahor, M.</creatorcontrib><creatorcontrib>Parini, A.</creatorcontrib><creatorcontrib>Rolland, Y.</creatorcontrib><creatorcontrib>Fielding, R. A.</creatorcontrib><creatorcontrib>Walston, J.</creatorcontrib><creatorcontrib>Vellas, B.</creatorcontrib><title>ICFSR Task Force Perspective on Biomarkers for Sarcopenia and Frailty</title><title>The Journal of Frailty & Aging</title><addtitle>J Frailty Aging</addtitle><addtitle>J Frailty Aging</addtitle><description>Biomarkers of frailty and sarcopenia are essential to advance the understanding of these conditions of aging and develop new diagnostic tools and effective treatments. The International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force - a group of academic and industry scientists from around the world — met in February 2019 to discuss the current state of biomarker development for frailty and sarcopenia. The D3Cr dilution method, which assesses creatinine excretion as a biochemical measure of muscle mass, was suggested as a more accurate measure of functional muscle mass than assessment by dual energy x-ray absorptiometry (DXA). Proposed biomarkers of frailty include markers of inflammation, the hypothalamic-pituitary-adrenal (HPA) axis response to stress, altered glucose insulin dynamics, endocrine dysregulation, aging, and others, acknowledging the complex multisystem etiology that contributes to frailty. Lack of clarity regarding a regulatory pathway for biomarker development has hindered progress; however, there are currently several international efforts to develop such biomarkers as tools to improve the treatment of individuals presenting these conditions.</description><subject>Advisory Committees</subject><subject>Age</subject><subject>Aging</subject><subject>Biological markers</subject><subject>Biomarkers</subject><subject>Chronic illnesses</subject><subject>Clinical trials</subject><subject>Congresses as Topic</subject><subject>Creatinine</subject><subject>Cytokines</subject><subject>Etiology</subject><subject>Frailty</subject><subject>Geriatrics/Gerontology</subject><subject>Glucose</subject><subject>Hormones</subject><subject>Humans</subject><subject>Hypothalamic-pituitary-adrenal axis</subject><subject>Inflammation</subject><subject>Insulin</subject><subject>Insulin-like growth factors</subject><subject>Internal Medicine</subject><subject>Life Sciences</subject><subject>Magnetic resonance imaging</subject><subject>Medicine</subject><subject>Medicine & Public Health</subject><subject>Musculoskeletal system</subject><subject>Neutrophils</subject><subject>Proteins</subject><subject>Rheumatology</subject><subject>Santé publique et épidémiologie</subject><subject>Sarcopenia</subject><subject>Special Article</subject><subject>Task forces</subject><subject>Tumor necrosis factor-TNF</subject><subject>Urine</subject><issn>2260-1341</issn><issn>2273-4309</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>C6C</sourceid><sourceid>EIF</sourceid><sourceid>7QJ</sourceid><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><sourceid>DWQXO</sourceid><recordid>eNptkc1LAzEQxYMoKtqbZwl4UXBrkkk2yVFLq0JB0XoO2d2srm43NWkL_e9NrR8gniZMfrx5Mw-hI0r6lDMFF6-17TNCdR_YFtpnTELGgejt9TsnGQVO91AvxqYgXGuVU6C7aA8YFYQRuY-Gt4PR4wOe2PiGRz6UDt-7EGeunDdLh32Hrxo_teEtNXHtA360ofQz1zUW267Co2Cbdr46RDu1baPrfdUD9DQaTgY32fju-nZwOc5KzvQ8q4ucc8Er6TiTVa1LoiQpQVFOKlkLVmiSKyGBE6a5Eq6ASthcSFUzIJwCHKCzje6Lbc0sNMnZynjbmJvLsVn3CBeQFMiSJvZ0w86Cf1-4ODfTJpaubW3n_CIaBlKkI3DFEnryB331i9ClTQzTAFTJZDtR5xuqDD7G4OofB5SYzzRMSsOs0zCwFj3-El0UU1f9wN-3T0C2AWL66p5d-J36r-AHgxWPBQ</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Rodriguez-Mañas, L.</creator><creator>Araujo de Carvalho, I.</creator><creator>Bhasin, S.</creator><creator>Bischoff-Ferrari, H. A.</creator><creator>Cesari, M.</creator><creator>Evans, W.</creator><creator>Hare, J. M.</creator><creator>Pahor, M.</creator><creator>Parini, A.</creator><creator>Rolland, Y.</creator><creator>Fielding, R. A.</creator><creator>Walston, J.</creator><creator>Vellas, B.</creator><general>Springer International Publishing</general><general>Springer Nature B.V</general><general>Springer</general><scope>C6C</scope><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>0-V</scope><scope>3V.</scope><scope>7QJ</scope><scope>7RV</scope><scope>7X7</scope><scope>7XB</scope><scope>8FI</scope><scope>8FJ</scope><scope>8FK</scope><scope>ABUWG</scope><scope>AFKRA</scope><scope>ALSLI</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>DWQXO</scope><scope>FYUFA</scope><scope>GHDGH</scope><scope>HEHIP</scope><scope>K9.</scope><scope>KB0</scope><scope>M0S</scope><scope>M2S</scope><scope>NAPCQ</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>7X8</scope><scope>1XC</scope><scope>VOOES</scope><orcidid>https://orcid.org/0000-0002-1157-0215</orcidid><orcidid>https://orcid.org/0009-0003-9486-9144</orcidid><orcidid>https://orcid.org/0000-0002-7678-5065</orcidid></search><sort><creationdate>20200101</creationdate><title>ICFSR Task Force Perspective on Biomarkers for Sarcopenia and Frailty</title><author>Rodriguez-Mañas, L. ; Araujo de Carvalho, I. ; Bhasin, S. ; Bischoff-Ferrari, H. A. ; Cesari, M. ; Evans, W. ; Hare, J. M. ; Pahor, M. ; Parini, A. ; Rolland, Y. ; Fielding, R. A. ; Walston, J. ; Vellas, B.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c429t-fb64454d7e427df9c0870c38140d7f52b90685734029485eb3d5a6578f2304133</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Advisory Committees</topic><topic>Age</topic><topic>Aging</topic><topic>Biological markers</topic><topic>Biomarkers</topic><topic>Chronic illnesses</topic><topic>Clinical trials</topic><topic>Congresses as Topic</topic><topic>Creatinine</topic><topic>Cytokines</topic><topic>Etiology</topic><topic>Frailty</topic><topic>Geriatrics/Gerontology</topic><topic>Glucose</topic><topic>Hormones</topic><topic>Humans</topic><topic>Hypothalamic-pituitary-adrenal axis</topic><topic>Inflammation</topic><topic>Insulin</topic><topic>Insulin-like growth factors</topic><topic>Internal Medicine</topic><topic>Life Sciences</topic><topic>Magnetic resonance imaging</topic><topic>Medicine</topic><topic>Medicine & Public Health</topic><topic>Musculoskeletal system</topic><topic>Neutrophils</topic><topic>Proteins</topic><topic>Rheumatology</topic><topic>Santé publique et épidémiologie</topic><topic>Sarcopenia</topic><topic>Special Article</topic><topic>Task forces</topic><topic>Tumor necrosis factor-TNF</topic><topic>Urine</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Rodriguez-Mañas, L.</creatorcontrib><creatorcontrib>Araujo de Carvalho, I.</creatorcontrib><creatorcontrib>Bhasin, S.</creatorcontrib><creatorcontrib>Bischoff-Ferrari, H. A.</creatorcontrib><creatorcontrib>Cesari, M.</creatorcontrib><creatorcontrib>Evans, W.</creatorcontrib><creatorcontrib>Hare, J. M.</creatorcontrib><creatorcontrib>Pahor, M.</creatorcontrib><creatorcontrib>Parini, A.</creatorcontrib><creatorcontrib>Rolland, Y.</creatorcontrib><creatorcontrib>Fielding, R. A.</creatorcontrib><creatorcontrib>Walston, J.</creatorcontrib><creatorcontrib>Vellas, B.</creatorcontrib><collection>Springer Nature OA Free Journals</collection><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Social Sciences Premium Collection</collection><collection>ProQuest Central (Corporate)</collection><collection>Applied Social Sciences Index & Abstracts (ASSIA)</collection><collection>Nursing & Allied Health Database</collection><collection>Health & Medical Collection</collection><collection>ProQuest Central (purchase pre-March 2016)</collection><collection>Hospital Premium Collection</collection><collection>Hospital Premium Collection (Alumni Edition)</collection><collection>ProQuest Central (Alumni) (purchase pre-March 2016)</collection><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>Social Science Premium Collection</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>ProQuest Central Korea</collection><collection>Health Research Premium Collection</collection><collection>Health Research Premium Collection (Alumni)</collection><collection>Sociology Collection</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Database (Alumni Edition)</collection><collection>Health & Medical Collection (Alumni Edition)</collection><collection>Sociology Database</collection><collection>Nursing & Allied Health Premium</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>MEDLINE - Academic</collection><collection>Hyper Article en Ligne (HAL)</collection><collection>Hyper Article en Ligne (HAL) (Open Access)</collection><jtitle>The Journal of Frailty & Aging</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Rodriguez-Mañas, L.</au><au>Araujo de Carvalho, I.</au><au>Bhasin, S.</au><au>Bischoff-Ferrari, H. A.</au><au>Cesari, M.</au><au>Evans, W.</au><au>Hare, J. M.</au><au>Pahor, M.</au><au>Parini, A.</au><au>Rolland, Y.</au><au>Fielding, R. A.</au><au>Walston, J.</au><au>Vellas, B.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>ICFSR Task Force Perspective on Biomarkers for Sarcopenia and Frailty</atitle><jtitle>The Journal of Frailty & Aging</jtitle><stitle>J Frailty Aging</stitle><addtitle>J Frailty Aging</addtitle><date>2020-01-01</date><risdate>2020</risdate><volume>9</volume><issue>1</issue><spage>4</spage><epage>8</epage><pages>4-8</pages><issn>2260-1341</issn><eissn>2273-4309</eissn><abstract>Biomarkers of frailty and sarcopenia are essential to advance the understanding of these conditions of aging and develop new diagnostic tools and effective treatments. The International Conference on Frailty and Sarcopenia Research (ICFSR) Task Force - a group of academic and industry scientists from around the world — met in February 2019 to discuss the current state of biomarker development for frailty and sarcopenia. The D3Cr dilution method, which assesses creatinine excretion as a biochemical measure of muscle mass, was suggested as a more accurate measure of functional muscle mass than assessment by dual energy x-ray absorptiometry (DXA). Proposed biomarkers of frailty include markers of inflammation, the hypothalamic-pituitary-adrenal (HPA) axis response to stress, altered glucose insulin dynamics, endocrine dysregulation, aging, and others, acknowledging the complex multisystem etiology that contributes to frailty. Lack of clarity regarding a regulatory pathway for biomarker development has hindered progress; however, there are currently several international efforts to develop such biomarkers as tools to improve the treatment of individuals presenting these conditions.</abstract><cop>Cham</cop><pub>Springer International Publishing</pub><pmid>32150207</pmid><doi>10.14283/jfa.2019.32</doi><tpages>5</tpages><orcidid>https://orcid.org/0000-0002-1157-0215</orcidid><orcidid>https://orcid.org/0009-0003-9486-9144</orcidid><orcidid>https://orcid.org/0000-0002-7678-5065</orcidid><oa>free_for_read</oa></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 2260-1341 |
| ispartof | The Journal of Frailty & Aging, 2020-01, Vol.9 (1), p.4-8 |
| issn | 2260-1341 2273-4309 |
| language | eng |
| recordid | cdi_hal_primary_oai_HAL_hal_04538570v1 |
| source | MEDLINE; ProQuest Central (Alumni Edition); Applied Social Sciences Index & Abstracts (ASSIA); ProQuest Central Korea; ProQuest Central UK/Ireland; SpringerLink Journals - AutoHoldings; ProQuest Central |
| subjects | Advisory Committees Age Aging Biological markers Biomarkers Chronic illnesses Clinical trials Congresses as Topic Creatinine Cytokines Etiology Frailty Geriatrics/Gerontology Glucose Hormones Humans Hypothalamic-pituitary-adrenal axis Inflammation Insulin Insulin-like growth factors Internal Medicine Life Sciences Magnetic resonance imaging Medicine Medicine & Public Health Musculoskeletal system Neutrophils Proteins Rheumatology Santé publique et épidémiologie Sarcopenia Special Article Task forces Tumor necrosis factor-TNF Urine |
| title | ICFSR Task Force Perspective on Biomarkers for Sarcopenia and Frailty |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-19T01%3A44%3A46IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_hal_p&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=ICFSR%20Task%20Force%20Perspective%20on%20Biomarkers%20for%20Sarcopenia%20and%20Frailty&rft.jtitle=The%20Journal%20of%20Frailty%20&%20Aging&rft.au=Rodriguez-Ma%C3%B1as,%20L.&rft.date=2020-01-01&rft.volume=9&rft.issue=1&rft.spage=4&rft.epage=8&rft.pages=4-8&rft.issn=2260-1341&rft.eissn=2273-4309&rft_id=info:doi/10.14283/jfa.2019.32&rft_dat=%3Cproquest_hal_p%3E2933187445%3C/proquest_hal_p%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2933187445&rft_id=info:pmid/32150207&rfr_iscdi=true |